--- title: "TG Therapeutics raises BRIUMVI sales guidance" url: "https://aibio.space/news/tg-therapeutics-raises-briumvi-sales-guidance-widens-buyback-300/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-05-06" section: "Financings" tickers: "NASDAQ:TGTX" source: "https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm" summary: "First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases." --- By the aibio.space TG desk. Sources - [TG Therapeutics (SEC 8-K)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm) - [TG Therapeutics 8-K (term loan)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/tgtx20260319_8k.htm) [TGTX](https://aibio.space/companies/tg-therapeutics/) 2026-05-06 # TG Therapeutics raises BRIUMVI sales guidance and widens buyback to $300 million Tickers [TGTX](https://aibio.space/companies/tg-therapeutics/) First-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases. ## Key facts - **Company**: TG Therapeutics, Inc. (NASDAQ: TGTX) - **News type**: Financings - **Primary source**: [TG Therapeutics (SEC 8-K)](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm) *An executive reading charts on a tablet. Photo: Olu Eletu, CC0, via StockSnap. The picture shows the field, not the companies named.* TG Therapeutics raised its 2026 U.S. BRIUMVI sales forecast to $885 million to $900 million from $825 million to $850 million on May 6, after first-quarter U.S. net sales of [$194.8 million](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm), up about 63% from a year earlier. It lifted its total revenue target to about $925 million. The company also said it had secured [$500 million more in non-dilutive capital from Blue Owl Capital](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm) and expanded its second share buyback to $300 million from $100 million. ## The details Total global revenue was about $205 million. Net product revenue was $201.3 million, including $6.5 million of sales to partner Neuraxpharm. Net income rose to $19.8 million from $5.1 million. Cash, cash equivalents and investment securities were $572.8 million at March 31, [per the release](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm). Selling, general and administrative expense rose to [$88.2 million from $50.3 million](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm) on higher marketing and media spending. Research and development expense was $48.4 million, including license and milestone costs under TG's agreement with Precision BioSciences, the source of azer-cel. TG gave second-quarter guidance of about $220 million in U.S. BRIUMVI sales. The financing came in March. An [8-K](https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/tgtx20260319_8k.htm) shows TG set up a $750 million term loan with Blue Owl, borrowed in full on March 18, 2026 and maturing in March 2031, and used part of it to repay its earlier $250 million loan. The deal also included an uncommitted facility of up to $250 million. ## Context Since starting buybacks in 2024, TG had repurchased $200 million of stock through April 30 at an average price of $29.28 a share, $100 million of it in the first quarter. The [10-Q for March 31](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015246/tgtx20260331_10q.htm) shows 153.1 million shares outstanding, down from 155.3 million at the end of 2025. [Chief executive Michael Weiss](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm) said growth came from "strong underlying demand, record new patient starts, and consistent commercial execution." He said TG sees BRIUMVI as having "multi-billion-dollar potential" before any effect from the subcutaneous version. In the quarter TG completed enrollment in phase 3 trials of subcutaneous BRIUMVI and of a single-infusion start. ## What it means for investors TG is borrowing to buy back stock and fund growth while it is profitable. That is a bet that BRIUMVI's cash flow will stay strong enough to carry about [$750 million of debt](https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/tgtx20260319_8k.htm). With sales growing more than 60% a year and guidance rising, the bet looks reasonable for now. It does raise the cost of a stumble, such as a competitive setback or a failed subcutaneous trial. The multi-billion-dollar claim is [management's view](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm), not a forecast, and it rests on continued share gains in a market with other anti-CD20 drugs, such as ocrelizumab. The buybacks reduce share count, but they also use cash that could fund pipeline work such as azer-cel and new indications. ## What to watch Second-quarter U.S. BRIUMVI sales, which TG guided to about $220 million, are the next test of the new forecast, per the [first-quarter release](https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/ex_926557.htm). Year-end 2026 or first quarter of 2027: subcutaneous phase 3 topline data. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story TGTX TG Therapeutics, Inc. NASDAQ ยท United States Open the desk ## More from the TG desk Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 --- Source page: https://aibio.space/news/tg-therapeutics-raises-briumvi-sales-guidance-widens-buyback-300/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "TG Therapeutics raises BRIUMVI sales guidance", 2026-05-06, https://aibio.space/news/tg-therapeutics-raises-briumvi-sales-guidance-widens-buyback-300/